Using a Monoclonal Antibody Plus Chemotherapy in Patients With DLBCL

home / case-based-roundtable-series / using-a-monoclonal-antibody-plus-chemotherapy-in-patients-with-dlbcl

This roundtable series gauges the use of combination CD19 inhibition and chemotherapy in the previously treated diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.

Tafasitamab/Lenalidomide Shows Efficacy, Tolerability for R/R DLBCL

Tafasitamab/Lenalidomide Shows Efficacy, Tolerability for R/R DLBCL

Targeted Oncology Staff
May 25th 2022

During a live virtual event, Brian T. Hill, MD, discussed the results of the L-MIND study of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse B-cell lymphoma.

Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL

Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL

Targeted Oncology Staff
June 20th 2022

During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.